Refine
Has Fulltext
- yes (32)
Is part of the Bibliography
- yes (32)
Year of publication
Document Type
- Journal article (32) (remove)
Language
- English (32)
Keywords
- theranostics (10)
- PET (8)
- prostate cancer (8)
- Positronen-Emissions-Tomografie (7)
- neuroendocrine tumor (7)
- radioligand therapy (7)
- CXCR4 (6)
- PRRT (6)
- PET/CT (5)
- PSMA (5)
- NET (3)
- peptide receptor radionuclide therapy (3)
- C-X-C motif chemokine receptor 4 (2)
- MAG3 (2)
- PSMA I&T (2)
- Prostate Cancer (2)
- RADS (2)
- SSTR (2)
- SUV (2)
- [68Ga]PentixaFor (2)
- chemokine receptor (2)
- endoradiotherapy (2)
- multiple myeloma (2)
- personalized medicine (2)
- positron emission tomography (2)
- prostate-specific membrane antigen (2)
- somatostatin receptor (2)
- 123I-Ioflupane (1)
- 177Lu (1)
- 18F-DCFPL (1)
- 18F-DCFPyL (1)
- 18F-FDG (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- Arginine (1)
- COVID-19 (1)
- CTCAE (1)
- CXCR4-targeting (1)
- DOTATOC (1)
- DaTscan (1)
- GCA (1)
- Ganglia (1)
- Hyperkalaemia (1)
- Imaging pitfalls (1)
- Lysine (1)
- MRI (1)
- Myocardial-perfusion SPECT (1)
- NEC (1)
- PMR (1)
- PSA (1)
- PSA response (1)
- PSMA-617 (1)
- PSMA-PET (1)
- PSMA-RADS (1)
- PSMA-TV (1)
- PSMA‐617 (1)
- Parkinsonism (1)
- Parkinson’s disease (1)
- Pitfall (1)
- Positron Emission Tomography (1)
- Prostata (1)
- RLT (1)
- Radiofluorine (1)
- Radiotracer (1)
- SARS-CoV-2 (1)
- SPECT (1)
- SPECT/CT (1)
- SSTR-PET (1)
- SSTR-RADS (1)
- Single-Photon-Emissions-Computertomographie (1)
- TKI (1)
- Tracer (1)
- Virchow Node (1)
- [177Lu]-DOTATATE/-DOTATOC (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]Lu-PSMA I&T (1)
- [177Lu]PentixaTher (1)
- [18F]FDG PET/CT (1)
- [68Ga] (1)
- [68Ga]DOTATOC (1)
- [68Ga]Pentixafor (1)
- [90Y]PentixaTher (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{177}\)Lu (1)
- \(^{18}\)F (1)
- \(^{18}\)F-PSMA-1007 (1)
- \(^{68}\)Ga (1)
- adrenocortical carcinoma (1)
- amino acids (1)
- combination (1)
- ejection fraction (1)
- fibroblast activation protein (1)
- flare phenomenon (1)
- giant cell arteritis (1)
- hematotoxicity (1)
- hyperkalemia (1)
- inflammation (1)
- kidney function (1)
- late response (1)
- left-ventricular function (1)
- matched pair (1)
- medicine (1)
- medullary thyroid carcinoma (1)
- molecular imaging (1)
- nephrotoxicity (1)
- overall survival (1)
- pancreas (1)
- papillary thyroid carcinoma (PTC) (1)
- polymyalgia rheumatica (1)
- prediction (1)
- prostate-specific membrane antigen (PSMA) (1)
- quantification (1)
- radioiodine (1)
- renal scintigraphy (1)
- reporting and data system (1)
- reporting and data systems (1)
- selpercatinib (1)
- solid tumors (1)
- somatostatin receptor (SSTR) (1)
- staging (1)
- standardization (1)
- standardized reporting system (1)
- taxane (1)
- thyroid carcinoma (TC) (1)
- tumor heterogeneity (1)
- tyrosine kinase inhibitor (1)
- vandetanib (1)
- vasculature (1)
- vasculitis (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (32)
- Medizinische Klinik und Poliklinik II (9)
- Urologische Klinik und Poliklinik (7)
- Medizinische Klinik und Poliklinik I (5)
- Comprehensive Cancer Center Mainfranken (2)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (2)
- Institut für Klinische Biochemie und Pathobiochemie (2)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Pathologisches Institut (2)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (9)
A growing body of literature reports on the upregulation of C-X-C motif chemokine receptor 4 (CXCR4) in a variety of cancer entities, rendering this receptor as suitable target for molecular imaging and endoradiotherapy in a theranostic setting. For instance, the CXCR4-targeting positron emission tomography (PET) agent [\(^{68}\)Ga]PentixaFor has been proven useful for a comprehensive assessment of the current status quo of solid tumors, including adrenocortical carcinoma or small-cell lung cancer. In addition, [\(^{68}\)Ga]PentixaFor has also provided an excellent readout for hematological malignancies, such as multiple myeloma, marginal zone lymphoma, or mantle cell lymphoma. PET-based quantification of the CXCR4 capacities in vivo allows for selecting candidates that would be suitable for treatment using the theranostic equivalent [\(^{177}\)Lu]/[\(^{90}\)Y]PentixaTher. This CXCR4-directed theranostic concept has been used as a conditioning regimen prior to hematopoietic stem cell transplantation and to achieve sufficient anti-lymphoma/-tumor activity in particular for malignant tissues that are highly sensitive to radiation, such as the hematological system. Increasing the safety margin, pretherapeutic dosimetry is routinely performed to determine the optimal activity to enhance therapeutic efficacy and to reduce off-target adverse events. The present review will provide an overview of current applications for CXCR4-directed molecular imaging and will introduce the CXCR4-targeted theranostic concept for advanced hematological malignancies.
Background
Labelled with lutetium-177, the urea-based small molecules PSMA I&T and PSMA-617 are the two agents most frequently used for radioligand therapy (RLT) in patients with advanced metastatic castration-resistant and prostate-specific membrane antigen (PSMA) expressing prostate cancer (mCRPC). In this matched-pair analysis, we aimed to compare the toxicity and efficacy of both agents for PSMA-directed RLT.
Materials and methods
A total of 110 mCRPC patients from two centres were accrued, 55 individuals treated with [\(^{177}\)Lu]Lu-PSMA I&T, and a matched cohort of 55 patients treated with [\(^{177}\)Lu]Lu-PSMA-617. Matching criteria included age at the first cycle, Gleason score, prostate-specific antigen (PSA) values, and previous taxane-based chemotherapy. Using common terminology criteria for adverse events (CTCAE v. 5.0), toxicity profiles were investigated (including bone marrow and renal toxicity). Overall survival (OS) between both groups was compared.
Results
Toxicity assessment revealed grade III anaemia in a single patient (1.8%) for [\(^{177}\)Lu]Lu-PSMA I&T and five (9.1%) for [\(^{177}\)Lu]Lu-PSMA-617. In addition, one (1.9%) grade III thrombopenia for [\(^{177}\)Lu]Lu-PSMA-617 was recorded. Apart from that, no other grade III/IV toxicities were present. A median OS of 12 months for patients treated with [\(^{177}\)Lu]Lu-PSMA I&T did not differ significantly when compared to patients treated with [\(^{177}\)Lu]Lu-PSMA-617 (median OS, 13 months; P = 0.89).
Conclusion
In this matched-pair analysis of patients receiving one of the two agents most frequently applied for PSMA RLT, the rate of clinically relevant toxicities was low for both compounds. In addition, no relevant differences for OS were observed.